Impact of rituximab therapy on response to tetanus toxoid vaccination in kidney-transplant patients

Experimental and Clinical Transplantation

Volumn 8, Issue 1, 2010, Pages 19-28

  Puissant Lubrano, Benedicte ^a,b   Rostaing, Lionel ^a,c   Kamar, Nassim ^a,c   Abbal, Michel ^a,b   Fort, Marylise ^a   Blancher, Antoine ^a,b  

^a CHU RANGUEIL   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c INSERM   (France)

Author keywords

B cell memory; Immunoglobulin level; Immunosuppressive regimen; Lymphocyte subsets; Secondary immune response

Indexed keywords

ANTIBODY; CALCINEURIN INHIBITOR; CORTICOSTEROID; IMMUNOGLOBULIN; RITUXIMAB; TETANUS TOXOID;

ANTIBODY BLOOD LEVEL; ARTICLE; B LYMPHOCYTE; BLOOD DONOR; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; MEMORY CELL; T LYMPHOCYTE; TETANUS PROPHYLAXIS; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CELL COUNT; FEMALE; GRAFT REJECTION; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULINS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TETANUS TOXOID;

EID: 77749311338     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med. 2008;359(3):242-251.
2. Stark K, Gunther M, Schonfeld C, Tullius SG, Bienzle U. Immunisations in solid-organ transplant recipients. Lancet. 2002;359(9310):957-965.
3. Gangappa S, Kokko KE, Carlson LM, et al. Immune responsiveness and protective immunity after transplantation. Transpl Int. 2008;21(4):293-303.
4. Huzly D, Neifer S, Reinke P, et al. Routine immunizations in adult renal transplant recipients. Transplantation. 1997;63(6):839-845.
5. WHO. Tetanus vaccine WHO position paper. WHO Weekly epidemiological record. 2006;81:197-208.
6. Gergen PJ, McQuillan GM, Kiely M, et al. A population-based serologic survey of immunity to tetanus in the United States. N Engl J Med. 1995;332(12):761-766.
7. Peltola H, Kayhty H, Virtanen M, Makela PH. Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med. 1984;310(24):1561-1566.
8. WHO. Diphtheria vaccine. WHO weekly epidemiological record. 2006:24-32.
9. CDC. Prevention of Pneumococcal Disease. CDC Recommendations of the Advisory Committee on Immunization Practices. 1997:1-24.
10. McNeil SA, Noya F, Dionne M, et al. Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adults. Vaccine. 2007;25(17):3464-3474.
11. Fazekas de St G,Webster RG. Disquisitions of Original Antigenic Sin. I. Evidence in man. J Exp Med. 1966;124(3):331-345.
12. Francois M, Buchler M, Halimi JM, et al. Lymphocyte subsets in renal transplant recipients treated with mycophenolate mofetil. Transplant Proc. 2000;32(8):2781-2782.
13. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther. 2006;8(3):R83.
14. Weigel G, Griesmacher A, Karimi A, et al. Effect of mycophenolate mofetil therapy on lymphocyte activation in heart transplant recipients. J Heart Lung Transplant. 2002;21(10):1074-1079.
15. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-celltargeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572-2581.
16. Maloney DG, Grillo-Lopez AJ,White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90(6):2188-2195.
17. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med. 2007;357(19):1903-1915.
18. Pichichero ME, Rennels MB, Edwards KM, et al. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA. 2005;293(24):3003-3011.
19. Willcocks LC, Chaudhry AN, Smith JC, et al. The effect of sirolimus therapy on vaccine responses in transplant recipients. Am J Transplant. 2007;7(8):2006-2011.
20. van der Velden AM, Claessen AM, van Velzen-Blad H, et al. Vaccination responses and lymphocyte subsets after autologous stem cell transplantation. Vaccine. 2007;25(51):8512-8517.
21. Oren S,MandelboimM, Braun-Moscovici Y, et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis. 2008;67(7):937-941.
22. van der Kolk LE, Baars JW, Prins MH, van Oers MH. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood. 2002;100(6):2257-2259.
23. Genberg H, Hansson A, Wernerson A, Wennberg L, Tyden G. Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant. 2006;6(10):2418-2428.
24. Schroder C, Azimzadeh AM, Wu G, et al. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl Immunol. 2003;12(1):19-28.
25. Steinmetz OM, Lange-Husken F, Turner JE, et al. Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection. Transplantation. 2007;84(7):842-850.
26. Thaunat O, Patey N, Gautreau C, et al. B cell survival in intragraft tertiary lymphoid organs after rituximab therapy. Transplantation. 2008;85(11):1648-1653.